4/18
09:11 am
coya
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit [Yahoo! Finance]
Low
Report
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit [Yahoo! Finance]
4/18
08:15 am
coya
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
Low
Report
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
4/8
08:15 am
coya
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
Low
Report
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
3/27
08:53 am
coya
We're Not Very Worried About Coya Therapeutics' (NASDAQ:COYA) Cash Burn Rate [Yahoo! Finance]
Medium
Report
We're Not Very Worried About Coya Therapeutics' (NASDAQ:COYA) Cash Burn Rate [Yahoo! Finance]
3/20
08:08 am
coya
Coya Therapeutics, Inc. (NASDAQ: COYA) had its price target raised by analysts at Chardan Capital from $11.00 to $14.00. They now have a "buy" rating on the stock.
Low
Report
Coya Therapeutics, Inc. (NASDAQ: COYA) had its price target raised by analysts at Chardan Capital from $11.00 to $14.00. They now have a "buy" rating on the stock.
3/19
08:33 am
coya
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results [Yahoo! Finance]
Low
Report
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results [Yahoo! Finance]
3/19
08:15 am
coya
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
Low
Report
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
3/13
09:31 am
coya
Thinking about buying stock in Vale SA, Virpax Pharmaceuticals, Paymentus, Futu Holdings, or Coya Therapeutics?
Medium
Report
Thinking about buying stock in Vale SA, Virpax Pharmaceuticals, Paymentus, Futu Holdings, or Coya Therapeutics?
3/12
09:00 am
coya
Coya Therapeutics to Participate in BTIG Fireside Discussion
Medium
Report
Coya Therapeutics to Participate in BTIG Fireside Discussion
3/12
08:31 am
coya
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference [Yahoo! Finance]
Medium
Report
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference [Yahoo! Finance]
3/12
08:00 am
coya
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
Medium
Report
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
3/6
08:15 am
coya
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
Low
Report
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
2/29
08:15 am
coya
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
Medium
Report
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
2/22
08:15 am
coya
Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference
Medium
Report
Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference
2/21
08:24 am
coya
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer's Disease and Coya's Pathway to a "Pipeline in a Product" [Yahoo! Finance]
Medium
Report
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer's Disease and Coya's Pathway to a "Pipeline in a Product" [Yahoo! Finance]
2/21
08:15 am
coya
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”
Medium
Report
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”
2/13
08:15 am
coya
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases
Low
Report
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases
1/29
08:15 am
coya
Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference
Low
Report
Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference